RISPERIDEX 3 MG

国家: 以色列

语言: 英文

来源: Ministry of Health

现在购买

资料单张 资料单张 (PIL)
10-11-2020
公众评估报告 公众评估报告 (PAR)
20-08-2020

有效成分:

RISPERIDONE

可用日期:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC代码:

N05AX08

药物剂型:

TABLETS

组成:

RISPERIDONE 3 MG

给药途径:

PER OS

处方类型:

Required

厂商:

DEXCEL LTD, ISRAEL

治疗组:

RISPERIDONE

治疗领域:

RISPERIDONE

疗效迹象:

Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years.Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

授权日期:

2021-05-31

其他语言的文件

资料单张 资料单张 阿拉伯文 10-11-2020
资料单张 资料单张 希伯来文 23-05-2019

搜索与此产品相关的警报